| Literature DB >> 30954716 |
Mathilde Berger1, Mona Amini-Adlé1, Laura Crumbach1, Etienne Paubelle2, Stéphane Dalle3.
Abstract
Entities:
Keywords: Immune checkpoint blocking agents; Immune related adverse events; Immunotherapy; Melanoma; PD1-inhibitor; Pure red cell aplasia; Thrombocytopaenia
Year: 2019 PMID: 30954716 DOI: 10.1016/j.ejca.2019.02.006
Source DB: PubMed Journal: Eur J Cancer ISSN: 0959-8049 Impact factor: 9.162